Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04856917 · ClinicalTrials.gov registry record · Phase 2

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris

A Phase 2 study of Acne Vulgaris, sponsored by Vanda Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
123
Enrollment target
15
Study locations

NCT04856917 is a Phase 2 study of Acne Vulgaris that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 123 participants, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (55% lower). The trial reports 15 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04856917, a Phase 2 study of Acne Vulgaris, has completed, sponsored by Vanda Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
123 participants
Enrollment target
15
Study locations

Study Summary

Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris

Conditions Studied

Acne Vulgaris

Interventions

  • BIOLOGICAL Placebo
  • DRUG Imsidolimab

Study Locations (15)

Florida

  • Site 10-113 - Sweetwater
  • Site 10-108 - Tampa
  • Site 10-107 - Tampa

Texas

  • Site 10-103 - Austin
  • Site 10-102 - College Station
  • Site 10-101 - San Antonio

California

  • Site 10-111 - Fountain Valley
  • Site 10-106 - Sherman Oaks

Louisiana

  • Site 10-109 - New Orleans
  • Site 10-112 - New Orleans

Arkansas

  • Site 10-114 - Hot Springs

Michigan

  • Site 10-104 - Detroit

New Hampshire

  • Site 10-110 - Portsmouth

Tennessee

  • Site 10-105 - Murfreesboro

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2021-05-15
Est. Completion 2022-03-29
Phase Phase 2

Sponsor

Vanda Pharmaceuticals

68 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04856917

The ClinicalTrials.gov registry entry for NCT04856917 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 274-participant average among 67 other Acne Vulgaris trials with a reported enrollment target (55% lower). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acne Vulgaris appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04856917 reports 15 study locations spanning 9 distinct geographic areas - top geographies include Florida, Texas, California.

Frequently Asked Questions

What is clinical trial NCT04856917 about?

NCT04856917 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris". Efficacy and Safety of Imsidolimab in Participants with Acne Vulgaris

What is the current status of trial NCT04856917?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 123 participants. The study started on 2021-05-15. Estimated completion is 2022-03-29.

What conditions does trial NCT04856917 study?

This clinical trial studies the following conditions: Acne Vulgaris.

What interventions are being tested in trial NCT04856917?

The interventions under investigation include: Placebo (BIOLOGICAL), Imsidolimab (DRUG).

Who is sponsoring clinical trial NCT04856917?

This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04856917 being conducted?

This trial has 15 study locations across Arkansas, California, Florida, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acne Vulgaris

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acne Vulgaris

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.